Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CERS
CERS logo

CERS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cerus Corp (CERS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.220
1 Day change
-1.83%
52 Week Range
3.470
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Cerus Corp is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has bullish short-term technical momentum and a favorable analyst upgrade, but the rally is extended and the RSI is overbought. With no recent news catalyst, no meaningful insider or hedge fund accumulation, and no bullish Intellectia proprietary signal, the better call is to wait rather than buy aggressively at this level.

Technical Analysis

CERS is in a clear uptrend: SMA_5 > SMA_20 > SMA_200, and MACD is positive and expanding, which supports bullish momentum. However, RSI_6 at 80.839 signals the stock is overbought, so the current price near 3.17 is not an ideal entry for a beginner. The stock is trading above pivot support at 2.854 and just below resistance R2 at 3.278, meaning upside exists but near-term follow-through may be limited after the recent move. The modeled trend also suggests modest near-term gains, but not enough to justify an aggressive immediate buy after a sharp run.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is strongly bullish. The open interest put-call ratio of 0.1 and option volume put-call ratio of 0.0 indicate calls dominate puts by a wide margin. Call open interest (6062) is much larger than put open interest (584), and today's volume is elevated versus the 30-day average. Implied volatility is high at 104.69, so the market expects large price movement, while IV rank is moderate. Overall, options traders are positioned bullishly, but the stock already looks extended.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
9

Positive Catalysts

  • ["BTIG upgraded Cerus to Buy from Neutral with a $4 price target on 2026-05-01.", "Technical trend remains bullish with SMA_5 > SMA_20 > SMA_200 and positive, expanding MACD.", "Options market sentiment is strongly bullish with very low put-call ratios.", "The pattern-based forecast suggests continued positive momentum over the next week and month."]

Neutral/Negative Catalysts

  • ["RSI_6 is 80.839, which is overbought and suggests the recent rally is stretched.", "No news in the recent week, so there is no fresh event-driven catalyst.", "Hedge funds are neutral and insiders are neutral, with no significant recent accumulation.", "No recent congress trading data is available.", "The stock is already close to the next resistance zone near 3.278."]

Financial Performance

Latest quarter financial data was not provided due to an error, so I cannot assess the most recent quarter's revenue or earnings growth. Based on the available dataset, there is no financial snapshot to confirm current fundamental acceleration. Because the latest quarter season is unavailable, the fundamental case remains unverified from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment has improved recently: BTIG upgraded Cerus to Buy from Neutral and assigned a $4 price target on 2026-05-01. That is a constructive sign and indicates Wall Street sees upside from current levels. Still, the broader pros and cons view is mixed: the buy rating is positive, but the lack of recent new catalysts, neutral insider/hedge fund activity, and stretched technicals temper enthusiasm.

Wall Street analysts forecast CERS stock price to rise
4 Analyst Rating
Wall Street analysts forecast CERS stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.280
sliders
Low
4
Averages
4.5
High
5
Current: 3.280
sliders
Low
4
Averages
4.5
High
5
BTIG
Neutral
to
Buy
upgrade
$4
AI Analysis
2026-05-01
Reason
BTIG
Price Target
$4
AI Analysis
2026-05-01
upgrade
Neutral
to
Buy
Reason
BTIG upgraded Cerus to Buy from Neutral with a $4 price target.
TD Cowen
TD Cowen
Buy
maintain
$5
2025-12-23
Reason
TD Cowen
TD Cowen
Price Target
$5
2025-12-23
maintain
Buy
Reason
TD Cowen says that Cerus' Intercept Fibrinogen Complex franchise represents an underappreciated long-term growth engine. The firm expects the newly announced BCA partnership to materially accelerate its adoption, scalability, and profitability across the U.S. blood center ecosystem. TD Cowen has increased confidence in the sustainability of Cerus' double digit revenue growth trajectory and views the current discounted valuation as attractive. The firm has a Buy rating on the shares with a price target of $5.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CERS
Unlock Now

People Also Watch